Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 May 5;5(5):CD002954.
doi: 10.1002/14651858.CD002954.pub3.

Drugs for discoid lupus erythematosus

Sue Jessop  1 , David A Whitelaw  2 , Matthew J Grainge  3 , Prativa Jayasekera  4
Affiliations
Meta-Analysis

Drugs for discoid lupus erythematosus

Sue Jessop et al. Cochrane Database Syst Rev. .

Abstract

Background: Discoid lupus erythematosus (DLE) is a chronic form of cutaneous lupus, which can cause scarring. Many drugs have been used to treat this disease and some (such as thalidomide, cyclophosphamide and azathioprine) are potentially toxic. This is an update of a Cochrane Review first published in 2000, and previously updated in 2009. We wanted to update the review to assess whether any new information was available to treat DLE, as we were still unsure of the effectiveness of available drugs and how to select the most appropriate treatment for an individual with DLE.

Objectives: To assess the effects of drugs for discoid lupus erythematosus.

Search methods: We updated our searches of the following databases to 22 September 2016: the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase and LILACS. We also searched five trials databases, and checked the reference lists of included studies for further references to relevant trials. Index Medicus (1956 to 1966) was handsearched and we approached authors for information about unpublished trials.

Selection criteria: We included all randomised controlled trials (RCTs) of drugs to treat people with DLE in any population group and of either gender. Comparisons included any drug used for DLE against either another drug or against placebo cream. We excluded laser treatment, surgery, phototherapy, other forms of physical therapy, and photoprotection as we did not consider them drug treatments.

Data collection and analysis: At least two reviewers independently extracted data onto a data extraction sheet, resolving disagreements by discussion. We used standard methods to assess risk of bias, as expected by Cochrane.

Main results: Five trials involving 197 participants were included. Three new trials were included in this update. None of the five trials were of high quality.'Risk of bias' assessments identified potential sources of bias in each study. One study used an inappropriate randomisation method, and incomplete outcome data were a concern in another as 15 people did not complete the trial. We found most of the trials to be at low risk in terms of blinding, but three of the five did not describe allocation concealment.The included trials inadequately addressed the primary outcome measures of this review (percentage with complete resolution of skin lesions, percentage with clearing of erythema in at least 50% of lesions, and improvement in patient satisfaction/quality of life measures).One study of fluocinonide cream 0.05% (potent steroid) compared with hydrocortisone cream 1% (low-potency steroid) in 78 people reported complete resolution of skin lesions in 27% (10/37) of participants in the fluocinonide cream group and in 10% (4/41) in the hydrocortisone group, giving a 17% absolute benefit in favour of fluocinonide (risk ratio (RR) 2.77, 95% CI 0.95 to 8.08, 1 study, n = 78, low-quality evidence). The other primary outcome measures were not reported. Adverse events did not require discontinuation of the drug. Skin irritation occurred in three people using hydrocortisone, and one person developed acne. Burning occurred in two people using fluocinonide (moderate-quality evidence).A comparative trial of two oral agents, acitretin (50 mg daily) and hydroxychloroquine (400 mg daily), reported two of the outcomes of interest: complete resolution was seen in 13 of 28 participants (46%) on acitretin and 15 of 30 participants (50%) on hydoxychloroquine (RR 0.93, 95% CI 0.54 to 1.59, 1 study, n = 58, low-quality evidence). Clearing of erythema in at least 50% of lesions was reported in 10 of 24 participants (42%) on acitretin and 17 of 25 (68%) on hydroxychloroquine (RR 0.61, 95% CI 0.36 to 1.06, 1 study, n = 49, low-quality evidence). This comparison did not assess improvement in patient satisfaction/quality of life measures. Participants taking acitretin showed a small increase in serum triglyceride, not sufficient to require withdrawal of the drug. The main adverse effects were dry lips (93% of the acitretin group and 20% of the hydroxychloroquine group) and gastrointestinal disturbance (11% of the acitretin group and 17% of the hydroxychloroquine group). Four participants on acitretin withdrew due to gastrointestinal events or dry lips (moderate-quality evidence).One trial randomised 10 people with DLE to apply a calcineurin inhibitor, pimecrolimus 1% cream, or a potent steroid, betamethasone 17-valerate 0.1% cream, for eight weeks. The study reported none of the primary outcome measures, nor did it present data on adverse events.A trial of calcineurin inhibitors compared tacrolimus cream 0.1% with placebo (vehicle) over 12 weeks in 14 people, but reported none of our primary outcome measures. In the tacrolimus group, five participants complained of slight burning and itching, and for one participant, a herpes simplex infection was reactivated (moderate-quality evidence).Topical R-salbutamol 0.5% cream was compared with placebo (vehicle) over eight weeks in one trial of 37 people with DLE. There was a significant improvement in pain and itch in the salbutamol group at two, four, six, and eight weeks compared to placebo, but the trial did not record a formal measure of quality of life. None of the primary outcome measures were reported. Changes in erythema did not show benefit of salbutamol over placebo, but we could not obtain from the trial report the number of participants with clearing of erythema in at least 50% of lesions. There were 15 events in the placebo group (experienced by 12 participants) and 24 in the salbutamol group (experienced by nine participants). None of the adverse events were considered serious (moderate-quality evidence).

Authors' conclusions: Fluocinonide cream may be more effective than hydrocortisone in clearing DLE skin lesions. Hydroxychloroquine and acitretin appear to be of equal efficacy in terms of complete resolution, although adverse effects might be more frequent with acitretin, and clearing of erythema in at least 50% of lesions occurred less often in participants applying acitretin. Moderate-quality evidence found adverse events were minor on the whole. There is not enough reliable evidence about other drugs used to treat DLE. Overall, the quality of the trials and levels of uncertainty were such that there is a need for further trials of sufficient duration comparing, in particular, topical steroids with other agents.

PubMed Disclaimer

Conflict of interest statement

Sue Jessop: I receive a small annual amount from royalties relating to the sale of a book on Primary Care Dermatology, which is not related to the subject of the review. David A Whitelaw: nothing to declare. Matthew J Grainge: nothing to declare. Prativa Jayasekera: nothing to declare.

Figures

1
1
Study flow diagram
2
2
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
1.1
1.1. Analysis
Comparison 1 Fluocinonide versus hydrocortisone cream, Outcome 1 Resolution of skin lesions.
2.1
2.1. Analysis
Comparison 2 Acitretin versus hydroxychloroquine, Outcome 1 Resolution of skin lesions.
2.2
2.2. Analysis
Comparison 2 Acitretin versus hydroxychloroquine, Outcome 2 Clearing of erythema.
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Barikbin 2009 {published data only}
    1. Barikbin B, Givrad S, Yousefi M, Eskandari F. Pimecrolimus 1% cream versus betamethasone 17‐valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double‐blind, randomized pilot study. Clinical and Experimental Dermatology 2009;34(7):776‐80. [PUBMED: 19456797] - PubMed
Jemec 2009 {published data only}
    1. Jemec GB, Ullman S, Goodfield M, Bygum A, Olesen AB, Berth‐Jones J, et al. A randomized controlled trial of R‐salbutamol for topical treatment of discoid lupus erythematosus. British Journal of Dermatology 2009;161(6):1365‐70. [PUBMED: 19681862] - PubMed
Kuhn 2011 {published data only}
    1. Kuhn A, Gensch K, Haust M, Schneider SW, Bonsmann G, Gaebelein‐Wissing N, et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double‐blind, vehicle‐controlled trial. Journal of the American Academy of Dermatology 2011;65(1):54‐64. [PUBMED: 21501887] - PubMed
Roenigk 1980 {published data only}
    1. Roenigk HH, Martin JS, Eichorn P, Gilliam JN. Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis; Cutaneous Medicine for the Practitioner 1980;25(3):281‐5. [PUBMED: 6987043] - PubMed
Ruzicka 1992 {published data only}
    1. Ruzicka T, Sommerburg C, Goerz G, Kind P, Mensing H. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. British Journal of Dermatology 1992;127(5):513‐8. [PUBMED: 1467292] - PubMed

References to studies excluded from this review

Avgerinou 2012 {published data only}
    1. Avgerinou G, Papafragkaki DK, Nasiopoulou A, Arapaki A, Katsambas A, Stavropoulos PG. Effectiveness of topical calcineurin inhibitors as monotherapy or in combination with hydroxychloroquine in cutaneous lupus erythematosus. Journal of the European Academy of Dermatology and Venereology : JEADV 2012;26(6):762‐7. [PUBMED: 21707772] - PubMed
Bezerra 2005 {published data only}
    1. Bezerra EL, Vilar MJ, Trindade Neto PB, Sato EI. Double‐blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus. Arthritis and Rheumatism 2005;52(10):3073‐8. [PUBMED: 16200586] - PubMed
Bjornberg 1963 {published data only}
    1. Bjornberg A, Hellgren L. Treatment of chronic discoid lupus erythematosus with fluocinolone acetonide ointment. British Journal of Dermatology 1963;75:156‐60. [PUBMED: 13971327] - PubMed
Furie 2015a {published data only}
    1. Furie RA, Leon G, Thomas M, Petrie MA, Chu AD, Hislop C, et al. A phase 2, randomised, placebo‐controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate‐to‐severe systemic lupus erythematosus, the PEARL‐SC study. Annals of the Rheumatic Diseases 2015;74(9):1667‐75. [PUBMED: 24748629] - PubMed
Furie 2015b {published data only}
    1. Furie R, Das M, Li D, Smythe S, Mathura E, Becker P. Repository corticotropin injection (H.P. acthar gel) attenuates disease activity in patients with persistently active systemic lupus erythematosus (SLE) requiring corticosteroids. Arthritis and Rheumatology 2015;67:no pagination. [CENTRAL: CN‐01162652; EMBASE: 72094616]
Gammon 2011 {published data only}
    1. Gammon B, Hansen C, Costner MI. Efficacy of mycophenolate mofetil in antimalarial‐resistant cutaneous lupus erythematosus. Journal of the American Academy of Dermatology 2011;65(4):717‐21. [PUBMED: 21641078] - PubMed
Islam 2012 {published data only}
    1. Islam NM, Hossain M, Haq SA, Alam NM, Klooster PM, Rasker JJ. Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus. International Journal of Rheumatic Diseases 2012;15(1):62‐8. [PUBMED: 22324948] - PubMed
Khamashta 2016 {published data only}
    1. Khamashta M, Merrill JT, Werth VP, Furie R, Kalunian K, Illei GG, et al. Sifalimumab, an anti‐interferon‐a monoclonal antibody, in moderate to severe systemic lupus erythematosus: A randomised, double‐blind, placebo‐controlled study. Annals of Rheumatic Diseases 2016;75(11):1909‐16. [PUBMED: 27009916] - PMC - PubMed
Kraak 1965 {published data only}
    1. Kraak JH, Ketel W, Prakken JR, Zwet W. The value of hydroxychloroquine (Plaquenil) for the treatment of chronic discoid lupus erythematosus; a double blind trial. Dermatologica 1965;130:293‐305. [PUBMED: 14333636] - PubMed
Kuhn 2011a {published data only}
    1. Kuhn A, Gensch K, Haust M, Meuth AM, Boyer F, Dupuy P, et al. Photoprotective effects of a broad‐spectrum sunscreen in ultraviolet‐induced cutaneous lupus erythematosus: a randomized, vehicle‐controlled, double‐blind study. Journal of the American Academy of Dermatology 2011;64(1):37‐48. [PUBMED: 21167404] - PubMed
Kuhn 2016 {published data only}
    1. Kuhn A, Landmann A, Patsinakidis N, Ruland V, Nozinic S, Perusquia Ortiz AM, et al. Fumaric acid ester treatment in cutaneous lupus erythematosus (SLE): a prospective, open‐label, phase II pilot study. Lupus 2016;25(12):1357‐64. [PUBMED: 27147621] - PubMed
Madan 2010 {published data only}
    1. Madan V, August PJ, Chalmers RJ. Efficacy of topical tacrolimus 0.3% in clobetasol propionate 0.05% ointment in therapy‐resistant cutaneous lupus erythematosus: a cohort study. Clinical and Experimental Dermatology 2010;35(1):27‐30. [PUBMED: 19549244] - PubMed
Manzi 2012 {published data only}
    1. Manzi S, Sánchez‐Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, et al. Effects of belimumab, a B lymphocyte stimulator‐specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Annals of the Rheumatic Diseases 2012;71(11):1833‐8. [PUBMED: 22550315] - PMC - PubMed
Merrill 2010a {published data only}
    1. Merrill JT, Burgos‐Vargas R, Westhovens R, Chalmers A, D'Cruz D, Wallace DJ, et al. The efficacy and safety of abatacept in patients with non‐life‐threatening manifestations of systemic lupus erythematosus: results of a twelve‐month, multicenter, exploratory, phase IIb, randomized, double‐blind, placebo‐controlled trial. Arthritis and Rheumatism 2010;62(10):3077‐87. [PUBMED: 20533545] - PubMed
Merrill 2010b {published data only}
    1. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: the randomized, double‐blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis and Rheumatism 2010;62(1):222‐33. [PUBMED: 20039413] - PMC - PubMed
Merrill 2011 {published data only}
    1. Merrill JT, Wallace DJ, Petri M, Kirou KA, Yao Y, White WI, et al. Safety profile and clinical activity of sifalimumab, a fully human anti‐interferon alpha monoclonal antibody, in systemic lupus erythematosus: A phase I, multicentre, double‐blind randomised study. Annals of the Rheumatic Diseases 2011;70(11):1905‐13. [PUBMED: 21798883] - PubMed
Ordi‐Ros 2000 {published data only}
    1. Ordi‐Ros J, Cortes F, Cucurull E, Mauri M, Bujan S, Vilardell M. Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy. Journal of Rheumatology 2000;27(6):1429‐33. [PUBMED: 10852265] - PubMed
Szepietowski 2013 {published data only}
    1. Szepietowski JC, Nilganuwong S, Wozniacka A, Kuhn A, Nyberg F, Vollenhoven RF, et al. Phase I, randomized, double‐blind, placebo‐controlled, multiple intravenous, dose‐ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis and Rheumatism 2013;65(10):2661‐71. [PUBMED: 23896980] - PubMed
Thivolet 1990 {published data only}
    1. Thivolet J, Nicolas JF, Kanitakis J, Lyonnet S, Chouvet B. Recombinant interferon alpha 2a is effective in the treatment of discoid and subacute cutaneous lupus erythematosus. British Journal of Dermatology 1990;122(3):405‐9. [PUBMED: 2182099] - PubMed
Tzung 2007 {published data only}
    1. Tzung TY, Liu YS, Chang HW. Tacrolimus vs clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double‐blind, bilateral comparison study. British Journal of Dermatology 2007;156(1):163‐201. - PubMed
Wang 2015 {published data only}
    1. Wang X, Zhang L, Luo J, Wu Z, Mei Y, Wang Y, et al. Tacrolimus 0.03% ointment in labial discoid lupus erythematosus: a randomized controlled clinical trial. Journal of Clinical Pharmacology 2015;55(11):1221‐8. [PUBMED: 25951426] - PubMed
Yokogawa 2015 {published data only}
    1. Yokogawa N, Takahashi T, Sato T, Yokota N. A double‐blind, randomized, parallel‐group study of hydroxychloroquine on cutaneous lupus erythematosus in Japan. Arthritis and Rheumatology 2015;67:no pagination. [CENTRAL: CN‐01162609; EMBASE: 72095665] - PubMed
Zhong 2013 {published data only}
    1. Zhong LLD, Bian ZX, Gu JH, Zhou X, Tian Y, Mao JC, et al. Chinese herbal medicine (Zi shen ging) for mild to moderate systemic lupus erythematosus: A pilot prospective single‐blinded randomised controlled study. Evidence‐based Complementary and Alternative Medicine : ECAM 2013;2013:327245. [CENTRAL: CN‐00906171; EMBASE: 2013362297] - PMC - PubMed

References to studies awaiting assessment

NCT00001680 {unpublished data only}
    1. NCT00001680. A pilot trial of topical thalidomide for the management of chronic discoid lupus erythematosus. clinicaltrials.gov/ct2/show/NCT00001680 date first received: 3 November 1999.
NCT00222183 {unpublished data only}
    1. NCT00222183. Cutaneous lupus erythematosus and elidel. clinicaltrials.gov/ct2/show/NCT00222183 date first received: 19 September 2005.
NCT00625157 {unpublished data only}
    1. NCT00625157. Efficacy and safety of ASF‐1096 cream 0.5% in the treatment of discoid lupus erythematosus (DLE) lesions (2). clinicaltrials.gov/ct2/show/NCT00625157 date first received: 20 February 2008.
NCT00625521 {published data only (unpublished sought but not used)}
    1. NCT00625521. Efficacy and safety of ASF‐1096 cream 0.5% in the treatment of discoid lupus erythematosus (DLE) lesions. clinicaltrials.gov/ct2/show/NCT00625521 date first received: 20 February 2008.
NCT01164917 {unpublished data only}
    1. NCT01164917. Safety study of AMG 811 in subjects with discoid lupus erythematosus. clinicaltrials.gov/ct2/show/NCT01164917 date first received: 15 July 2010.
NCT01300208 {unpublished data only}
    1. NCT01300208. To evaluate the preliminary safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of CC‐11050 in subjects with discoid lupus erythematosus and subacute cutaneous lupus erythematosus. clinicaltrials.gov/ct2/show/NCT01300208 date first received: 18 October 2010.
NCT01407679 {unpublished data only}
    1. NCT01407679. Efficacy and safety of oral alitretinoin (Toctino®) in the treatment of patients with cutaneous lupus erythematosus (AliCLE). clinicaltrials.gov/ct2/show/NCT01407679 date first received: 1 August 2011.
NCT01597050 {published data only}
    1. NCT01597050. Safety and efficacy of topical R333 in patients with discoid lupus erythematosus (DLE) and systemic lupus erythematosus (SLE) lesions (SKINDLE). clinicaltrials.gov/ct2/show/NCT01597050 date first received: 9 May 2012.
Pothinamthong 2012 {published data only}
    1. Pothinamthong P, Janjumratsang P. A comparative study in efficacy and safety of 0.1% tacrolimus and 0.05% clobetasol propionate ointment in discoid lupus erythematosus by modified cutaneous lupus erythematosus disease area and severity index. Journal of the Medical Association of Thailand= Chotmaihet Thangphaet 2012;95(7):933‐40. [PUBMED: 22919989] - PubMed

References to ongoing studies

NCT02927457 {unpublished data only}
    1. NCT02927457. Safety, tolerability, pharmacokinetics, pharmacodynamics and clinical effect of GSK2646264 in cutaneous lupus erythematosus patients [A double‐blind (sponsor unblinded) study to investigate safety, tolerability, pharmacokinetics, pharmacodynamics and clinical effect of repeat dosing of GSK2646264 in cutaneous lupus erythematosus patients]. clinicaltrials.gov/ct2/show/NCT02927457 Date first received: 30 August 2016.

Additional references

Albrecht 2005
    1. Albrecht J, Taylor L, Berlin JA, Dulay S, Ang G, Fakharzadeh S, et al. The CLASI (Cutaneous Lupus Erythematosus disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. Journal of Investigative Dermatology 2005;125(5):889‐94. [PUBMED: 16297185] - PMC - PubMed
Artuz 1996
    1. Artuz F, Lenk N, Deniz N, Alli N. Efficacy of sulphasalazine in discoid lupus erythematosus. International Journal of Dermatology 1996;35(10):746‐8. [PUBMED: 8891833] - PubMed
Brodthagen 1959
    1. Brodthagen H. Hydroxychloroquine (Plaquenil) in the treatment of lupus erythematosus. Acta Dermato‐venereologica 1959;39:233‐7. [PUBMED: 13804646] - PubMed
Callen 1982
    1. Callen JP. Chronic cutaneous lupus erythematosus. Clinical, laboratory, therapeutic, and prognostic examination of 62 patients. Archives of Dermatology 1982;118(6):412‐6. [PUBMED: 7092253] - PubMed
Callen 1997
    1. Callen JP. Management of antimalarial‐refractory cutaneous lupus erythematosus. Lupus 1997;6(2):203‐8. [PUBMED: 9061669] - PubMed
Chasset 2015
    1. Chasset F, Francès C, Barete S, Amoura Z, Arnaud l. Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta‐analysis of the literature. Journal of the American Academy of Dermatology 2015;72(4):634‐9. [PUBMED: 25648824] - PubMed
Coburn 1982
    1. Coburn PR, Shuster S. Dapsone and discoid lupus erythematosus. British Journal of Dermatology 1982;106(1):105‐6. [PUBMED: 7059497] - PubMed
Cortés‐Hernández 2012
    1. Cortés‐Hernández J, Torres‐Salido M, Castro‐Marrero J, Vilardell‐Tarres M, Ordi‐Ros J. Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome. British Journal of Dermatology 2012;166(3):616‐23. [PUBMED: 21999437] - PubMed
Dalziel 1986
    1. Dalziel K, Going S, Cartwright PH, Marks R, Beveridge GW, Rowell NR. Treatment of chronic discoid lupus erythematosus with an oral gold compound (auranofin). British Journal of Dermatology 1986;115(2):211‐6. [PUBMED: 3091062] - PubMed
Egger 1997
    1. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315(7109):629‐634. [PUBMED: 9310563] - PMC - PubMed
Feldman 1994
    1. Feldman R, Salomon D, Saurat JH. The association of the two antimalarials chloroquine and quinacrine for treatment‐resistant chronic and subacute cutaneous lupus erythematosus. Dermatology 1994;189(4):425‐7. [PUBMED: 7873836] - PubMed
Fernandes 2015
    1. Fernandes MS, Girisha BS, Viswanathan N, Sripathi H, Noronha TM. Discoid lupus erythematosus with squamous cell carcinoma: a case report and review of the literature in Indian patients. Lupus 2015;24(14):1562‐6. [PUBMED: 26251401] - PubMed
Geamanu 2014
    1. Geamanu Panca A, Popa‐Cherecheanu A, Marinescu B, Geamănu CD, Voinea LM. Retinal toxicity associated with chronic exposure to hydroxychloroquine and its ocular screening. Review. Journal of Medicine and Life 2014;7(3):322‐326. [PUBMED: 25408748] - PMC - PubMed
Goldberg 2015
    1. Goldberg R, Irving P. Toxicity and response to thiopurines in patients with inflammatory bowel disease. Expert Review of Gastroenterology & Hepatology 2015;9(7):891‐900. [PUBMED: 25915575] - PubMed
Goldman 1953
    1. Goldman L, Cole DP, Preston RH. Chloroquine diphosphate in treatment of discoid lupus erythematosus. Journal of the American Medical Association 1953;152(15):1428‐9. [PUBMED: 13061294] - PubMed
Goldstein 1994
    1. Goldstein E, Carey W. Discoid lupus erythematosus: successful treatment with oral methotrexate. Archives of Dermatology 1994;130(7):938‐9. [PUBMED: 8024288] - PubMed
Hasper 1983
    1. Hasper MF. Chronic cutaneous lupus erythematosus. Thalidomide treatment of 11 patients. Archives of Dermatology 1983;119(10):812‐5. [PUBMED: 6614949] - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Jansen 1965
    1. Jansen GT, Dillaha CJ, Honeycutt WM. Discoid lupus erythematosus. Is systemic treatment necessary?. Archives of Dermatology 1965;92(3):283‐5. [PUBMED: 11851251] - PubMed
Khandpur 2004
    1. Khandpur S, Sharma VK, Sumanth K. Topical immunomodulators in dermatology. Journal of Postgraduate Medicine 2004;50(2):131‐9. [PUBMED: 15235214] - PubMed
Kierland 1953
    1. Kierland RR, Brunsting LA, O'Leary PA. Quinacrine hydrochloride (atabrine) in the treatment of lupus erythematosus. Archives of Dermatology and Syphilology 1953;68(6):651‐9. [PUBMED: 13103808] - PubMed
Knop 1983
    1. Knop J, Bonsmann G, Happle R, Ludolph A, Matz DR, Mifsud EJ, et al. Thalidomide in the treatment of 60 cases of chronic discoid lupus erythematosus. British Journal of Dermatology 1983;108:461‐6. - PubMed
Kraak 1964
    1. Kraak JH. Local treatment of chronic lupus erythematosus with triamcinolone injections [Lokale behandeling van chronische (lupus) erythematodes]. Nederlands Tijdschrift voor Geneeskunde 1964;108:1305‐6. [PUBMED: 14177187] - PubMed
Kreuter 2009
    1. Kreuter A, Gaifullina R, Tigges C, Kirschke J, Altmeyer P, Gambichler T. Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking. Archives of Dermatology 2009;145(3):244‐8. [PUBMED: 19289751] - PubMed
Kuhn 2014
    1. Kuhn A, Landmann A. The classification and diagnosis of cutaneous lupus erythematosus. Journal of Autoimmunity 2014;48‐49:14‐9. [PUBMED: 24486120] - PubMed
Lindskov 1986
    1. Lindskov R, Reymann F. Dapsone in the treatment of cutaneous lupus erythematosus. Dermatologica 1986;172(4):214‐7. [PUBMED: 3519302] - PubMed
Mackey 1974
    1. Mackey JP, Barnes J. Clofazimine in the treatment of discoid lupus erythematosus. British Journal of Dermatology 1974;91(1):93‐6. [PUBMED: 4851057] - PubMed
Maguire 1962
    1. Maguire A. Amodiaquine hydrochloride in the treatment of chronic discoid lupus erythematosus. Lancet 1962;1(7231):665‐7. [PUBMED: 14468396] - PubMed
Marsden 1968
    1. Marsden CW. Fluocinolone acetonide 0.2 per cent cream ‐ a co‐operative clinical trial. British Journal of Dermatology 1968;80(9):614‐7. [PUBMED: 4877599] - PubMed
Martinez 1992
    1. Martinez J, Misa RF, Torrelo A, Ledo A. A low‐dose intralesional interferon alfa for discoid lupus erythematosus. Journal of the American Academy of Dermatology 1992;26(3 Pt 2):494‐6. [PUBMED: 1564159] - PubMed
Naafs 1985
    1. Naafs B, Faber WR. Thalidomide therapy. An open trial. International Journal of Dermatology 1985;24(2):131‐4. [PUBMED: 2985516] - PubMed
Norris 2005
    1. Norris DA. Mechanisms of action of topical therapies and the rationale for combination therapy. Journal of the American Academy of Dermatology 2005;53(1 Suppl 1):S17‐25. [PUBMED: 15968260] - PubMed
Okon 2014
    1. Okon L, Rosenbach M, Krathen M, Rose M, Propert K, Okawa J, et al. Lenalidomide in treatment‐refractory cutaneous lupus erythematosus: Efficacy and safety in a 52‐week trial. Journal of American Academy of Dermatology 2014;70(3):583‐4. [PUBMED: 24528907] - PMC - PubMed
Ortiz 2013
    1. Ortiz NE, Nijhawan RI, Weinberg JM. Acitretin. Dermatologic Therapy 2013;26(5):390‐9. [PUBMED: 24099069] - PubMed
Prakken 1961
    1. Prakken JR. Difficulty in judging the value of therapy. Observations in connection with reports on the treatment of chronic lupus erythematosus [Oorspronkelijke Stukken. Het moeilijke oordeel over de waarde van een therapie]. Nederlands Tijdschrift voor Geneeskunde 1961;105:971‐6. [PUBMED: 13737707] - PubMed
Rainsford 2015
    1. Rainsford KD, Parke AL, Clifford‐Rashotte M, Kean WF. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology 2015;23(5):231‐69. [PUBMED: 26246395] - PubMed
Rees 1963
    1. Rees RB, Maibach HI. Chloroquine. A review of reactions and dermatologic indications. Archives of Dermatology 1963;88:280‐9. [PUBMED: 14043620] - PubMed
Reyman 1974
    1. Reyman F. Treatment of discoid lupus erythematosus with betametasone‐valerate cream 1 percent. Dermatologica 1974;149(2):65‐8. [PUBMED: 4615953] - PubMed
Rodriguez‐Castellanos 1995
    1. Rodriguez‐Castellanos MA, Barba Rubio J, Barba Gomez JF, Gonzalez Mendoza A. Phenytoin in the treatment of discoid lupus erythematosus. Archives of Dermatology 1995;131(5):620‐1. [PUBMED: 7741559] - PubMed
Rothfield 1963
    1. Rothfield NF, March C, Miescher P, McEwen C. Chronic discoid lupus erythematosus ‐ a study of 65 patients and 65 controls. New England Journal of Medicine 1963;269:1155‐61. - PubMed
Ruzicka 1988
    1. Ruzicka T, Meurer M, Bieber T. Efficiency of acitretin in the treatment of cutaneous lupus erythematosus. Archives of Dermatology 1988;124(6):897‐902. [PUBMED: 2967674] - PubMed
Schroeder 2007
    1. Schroeder M, Zouboulis CC. All‐trans‐retinoic acid and 13‐cis‐retinoic acid: pharmacokinetics and biological activity in different cell culture models of human keratinocytes. Hormone Metabolism Research 2007;39(2):136‐40. [PUBMED: 17326009] - PubMed
Shornick 1991
    1. Shornick JK, Formica N, Parke AL. Isotretinoin for refractory lupus erythematosus. Journal of the American Academy of Dermatology 1991;24(1):49‐52. [PUBMED: 1999529] - PubMed
Smith 1986
    1. Smith JF. Intralesional triamcinolone as an adjunct to antimalarial drugs in the treatment of chronic discoid lupus erythematosus. British Journal of Dermatology 1962;74:350‐3. [PUBMED: 13989464] - PubMed
Tsellos 2008
    1. Tzellos TG, Kouvelas D. Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence‐based evaluation. European Journal of Clinical Pharmacology 2008;64(4):337‐41. [PUBMED: 18157526] - PubMed
Tsokos 1985
    1. Tsokos GC, Caughman SW, Klippel JH. Successful treatment of generalized discoid skin lesions with azathioprine. Its use in a patient with systemic lupus erythematosus. Archives of Dermatology 1985;121(10):1323‐5. [PUBMED: 4037829] - PubMed
Usmani 2007
    1. Usmani N, Goodfield M. Efalizumab in the treatment of discoid lupus erythematosus. Archives of Dermatology 2007;143(7):873‐7. [PUBMED: 17638731] - PubMed
Vasquez 2013
    1. Vasquez R, Wang D, Tran QP, Adams‐Huet B, Chren MM, Costner MI, et al. A multicentre, cross‐sectional study on quality of life in patients with cutaneous lupus erythematosus. British Journal of Dermatology 2013;168(1):145‐53. [PUBMED: 22708924] - PMC - PubMed
Weinblatt 2013
    1. Weinblatt ME. Methotrexate in rheumatoid arthritis: a quarter century of development. Transactions of the American Clinical and Climatological Association 2013;124:16‐25. [PUBMED: 23874006] - PMC - PubMed
Wollina 2007
    1. Wollina U, Hansel G. The use of topical calcineurin inhibitors in lupus erythematosus: an overview. Journal of the European Academy of Dermatology and Venereology : JEADV 2008;22(1):1‐6. [PUBMED: 18005117] - PubMed
Zhou 2013
    1. Zhou S, Wang F, Hsieh TC, Wu JM, Wu E. Thalidomide ‐ a notorious sedative to a wonder anticancer drug. Current Medicinal Chemistry 2013;20(33):4102‐8. [PUBMED: 23931282] - PMC - PubMed

References to other published versions of this review

Jessop 2000
    1. Jessop S, Whitelaw D, Jordaan F. Drugs for discoid lupus erythematosus. Cochrane Database of Systematic Reviews 2000, Issue 2. [DOI: 10.1002/14651858.CD002954] - DOI - PubMed
Jessop 2009
    1. Jessop S, Whitelaw DA, Delamere FM. Drugs for discoid lupus erythematosus. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD002954.pub2] - DOI - PubMed

MeSH terms